Literature DB >> 27812682

Harnessing the Immune System as a Therapeutic Tool in Virus-Associated Cancers.

Rafael Santana-Davila1, Shailender Bhatia1, Laura Q M Chow1.   

Abstract

IMPORTANCE: There are at least 7 viruses implicated in the pathogenesis of 10% to 15% of all human cancers worldwide. Despite a high prevalence of infection with these viruses, only a minority of infected individuals develop a subsequent malignant tumor, underscoring the important role that host and environmental factors have in cancer development. This article reviews the mechanisms of viral carcinogenesis, with an emphasis on the viral evasion of the host immune system, and discusses how to harness the immune system effectively as a therapeutic tool in select cancers. OBSERVATIONS: Immune evasion mechanisms of these viral infections have an important role in carcinogenesis. Increased understanding of these mechanisms has paved the way for using immunotherapy to treat virus-associated cancers. This study summarizes the use of adoptive cell therapy, tumor vaccines, immune checkpoint inhibitors, and combination immunotherapies in the treatment of select virus-associated cancers. CONCLUSIONS AND RELEVANCE: Immunotherapy is proving to be a useful strategy in the treatment of virus-associated cancers. A greater understanding of the processes of immune evasion in chronic infections and malignant tumors will continue to help in the goal of optimizing immunotherapy, which will in turn translate into remission and long-term survival in this patient population.

Entities:  

Mesh:

Year:  2017        PMID: 27812682     DOI: 10.1001/jamaoncol.2016.4574

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


  6 in total

Review 1.  Cholangiocarcinoma - evolving concepts and therapeutic strategies.

Authors:  Sumera Rizvi; Shahid A Khan; Christopher L Hallemeier; Robin K Kelley; Gregory J Gores
Journal:  Nat Rev Clin Oncol       Date:  2017-10-10       Impact factor: 66.675

Review 2.  The Anticancer Potential of T Cell Receptor-Engineered T Cells.

Authors:  Matyas Ecsedi; Megan S McAfee; Aude G Chapuis
Journal:  Trends Cancer       Date:  2020-09-26

Review 3.  The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma.

Authors:  Oraianthi Fiste; Ioannis Ntanasis-Stathopoulos; Maria Gavriatopoulou; Michalis Liontos; Konstantinos Koutsoukos; Meletios Athanasios Dimopoulos; Flora Zagouri
Journal:  Vaccines (Basel)       Date:  2021-04-22

4.  A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma.

Authors:  Cecilia Monge; Erica C Pehrsson; Changqing Xie; Austin G Duffy; Donna Mabry; Bradford J Wood; David E Kleiner; Seth M Steinberg; William D Figg; Bernadette Redd; Anuradha Budhu; Sophie Wang; Mayank Tandon; Lichun Ma; Xin Wei Wang; Tim F Greten
Journal:  Oncologist       Date:  2022-03-11

5.  Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade.

Authors:  Minghao Sui; Yu Li; Hongguang Wang; Ying Luo; Tao Wan; Xun Wang; Bingyang Hu; Yanshuang Cheng; Xianrong Lv; Xianlei Xin; Qiang Xu; Guan Wang; Shichun Lu
Journal:  J Immunother Cancer       Date:  2019-05-07       Impact factor: 13.751

Review 6.  New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.

Authors:  Sara Massironi; Lorenzo Pilla; Alessandra Elvevi; Raffaella Longarini; Roberta Elisa Rossi; Paolo Bidoli; Pietro Invernizzi
Journal:  Cells       Date:  2020-03-11       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.